TrademarkDir
CRISPR BY DESIGN
LIVE

Serial Number

90981354

Owner

Scribe Therapeutics Inc.

Attorney

John Paul Oleksiuk

Filing Date

Mar 23, 2021

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

CRISPR BY DESIGN Trademark

Serial Number: 90981354 • Registration: 7689563

CRISPR BY DESIGN is a trademark filed by Scribe Therapeutics Inc. on March 23, 2021. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Scribe Therapeutics Inc. (10 trademarks)

Alameda, CA 94501

Entity Type: 03

Trademark Details

Filing Date

March 23, 2021

Registration Date

February 11, 2025

Published for Opposition

June 21, 2022

Goods & Services

Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, diagnostic and therapeutic products and services; design and development of engineered cells for use in scientific research and drug discovery and development; Providing medical research and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 11, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 11, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jan 21, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jan 21, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Dec 16, 2024 SUPC
DIVISIONAL PROCESSING COMPLETE
Dec 16, 2024 DPCC
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 16, 2024 EXRA
SOU EXTENSION 4 GRANTED
Dec 16, 2024 EX4G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 22, 2024 AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 18, 2024 AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 23, 2024 AITU
USE AMENDMENT FILED
Aug 19, 2024 IUAF
DIVISIONAL REQUEST RECEIVED
Aug 19, 2024 DRRR
TEAS STATEMENT OF USE RECEIVED
Aug 19, 2024 EISU
TEAS REQUEST TO DIVIDE RECEIVED
Aug 19, 2024 ERTD
SOU EXTENSION 4 FILED
Aug 14, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Aug 14, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 9, 2024 EXRA
SOU EXTENSION 3 GRANTED
Feb 8, 2024 EX3G
SOU EXTENSION 3 FILED
Feb 8, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 8, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 12, 2023 EXRA
SOU EXTENSION 2 GRANTED
Aug 10, 2023 EX2G
SOU EXTENSION 2 FILED
Aug 10, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 10, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 10, 2023 EXRA
SOU EXTENSION 1 GRANTED
Feb 8, 2023 EX1G
SOU EXTENSION 1 FILED
Feb 8, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 8, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 16, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 21, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 21, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 1, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 19, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 26, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 26, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 26, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 28, 2021 GNRN
NON-FINAL ACTION E-MAILED
Oct 28, 2021 GNRT
NON-FINAL ACTION WRITTEN
Oct 28, 2021 CNRT
ASSIGNED TO EXAMINER
Oct 27, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 28, 2021 NWOS
NEW APPLICATION ENTERED
Mar 26, 2021 NWAP

Related Trademarks

More from this Owner

CRISPR BY DESIGN

CRISPR BY DESIGN

CRISPR BY DESIGN

CRISPR BY DESIGN

ELXR

ELXR

ELXR

ELXR

X SCRIBE THERAPEUTICS logo

X SCRIBE THERAPEUTICS

X SCRIBE THERAPEUTICS logo

X SCRIBE THERAPEUTICS